title: Clinical outcome of acute pneumococcal otitis media and serum antibody responses to pneumococcal pneumolysin and polysaccharides in children.
abstract: Serum antibody responses to pneumococcal antigens and their relationship to the clinical outcome were determined in a prospective study of 121 children with acute otitis media (AOM). Pneumococcus positive children with a pneumolysin response more often had a recurrence and middle ear effusion (MEE) after 1 month than did the non-responders (p = 0.005 and p = 0.04, respectively). All the children who responded to pneumolysin also had clinically strong symptoms and signs of AOM. Children who responded to pneumococcal polysaccharides developed otitis media with effusion within a 6-month follow-up period more often than did the non-responders (p = 0.005). The results of this study suggest that children with pneumococcal AOM and an antibody response to the intracellular pneumococcal protein pneumolysin behave clinically differently from children with an antibody response to polysaccharides.
authors.affiliation: Department of Otolaryngology, University of Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Jero
authors.forename: A
authors.initials: A
authors.lastname: Virolainen
authors.forename: P
authors.initials: P
authors.lastname: Karma
mesh_terms: D000208:Acute Disease; D000942:Antigens, Bacterial / Q000097:blood / Q000276:immunology; D001329:Autolysis / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology*; D007223:Infant; D010033:Otitis Media / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D010034:Otitis Media with Effusion / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D012008:Recurrence; D013296:Streptococcus pneumoniae / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000942:Antigens, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines